Introduction
India plays a magnificent role in the global clinical trials, leveraging the country’s diverse population and reformed regulations, which help in drug innovations. In 2024, India alone registered 18,000 new trials, which is a 50% jump from the previous year. As a result, India is now positioned as a top destination globally.
Regulatory Reforms Fuel Growth
The New Drugs and Clinical Trials Rules of 2019 have optimized the approval process, which in turn has boosted patient safety and aligned with international standards, drawing global sponsors. This has helped reduce the timelines and built trust with some of the major companies like Bristol Myers Squibb, investing over $ 100 million in R&D hubs.
Key Contributions
India is a preferred destination globally for the following reasons:
- Cost efficiency
- Skilled workforce
- Vast patient pool
All these have contributed to accelerated trials for vaccines, generics and novel therapies. India is the leading supplier of vaccines, contributing 50% of global vaccines, and excels notably in phase 3 studies, also aiding in FDA approval for drugs used in heart disease.
Challenges and Future
While the growth hits 8% CAGR and is expected to hit $90 billion globally by 2035, one of the major issues that still persists is ethical oversight. India has been aiming for 10-12% of world trials by 2030 through tech and partnerships. These efforts not only speed innovation but also help to improve the local healthcare on a large scale.
How can India balance rapid trial growth with ethical standards to lead global research responsibly?
MBH/AB